Eaton Vance Management trimmed its holdings in Agilent Technologies, Inc. (NYSE:A) by 6.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,000,011 shares of the medical research company’s stock after selling 73,292 shares during the quarter. Eaton Vance Management’s holdings in Agilent Technologies were worth $127,141,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in A. Jackson Grant Investment Advisers Inc. acquired a new position in Agilent Technologies in the fourth quarter valued at approximately $33,000. Piscataqua Savings Bank acquired a new position in Agilent Technologies in the first quarter valued at approximately $35,000. GPS Wealth Strategies Group LLC acquired a new position in Agilent Technologies in the first quarter valued at approximately $38,000. RMR Wealth Builders boosted its holdings in Agilent Technologies by 552.0% in the first quarter. RMR Wealth Builders now owns 326 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 276 shares in the last quarter. Finally, Allred Capital Management LLC purchased a new stake in Agilent Technologies in the first quarter valued at approximately $44,000.
In other news, SVP Michael Tang sold 500 shares of the firm’s stock in a transaction dated Friday, April 23rd. The stock was sold at an average price of $137.00, for a total transaction of $68,500.00. Following the completion of the sale, the senior vice president now directly owns 53,030 shares in the company, valued at $7,265,110. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jacob Thaysen sold 16,289 shares of the firm’s stock in a transaction dated Thursday, June 10th. The shares were sold at an average price of $142.90, for a total value of $2,327,698.10. Following the sale, the vice president now owns 83,423 shares of the company’s stock, valued at $11,921,146.70. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,800 shares of company stock worth $5,172,352.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Monday, May 24th. The medical research company reported $0.97 EPS for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.15. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.39 billion. Agilent Technologies had a net margin of 15.90% and a return on equity of 24.14%. The firm’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.71 EPS. Analysts forecast that Agilent Technologies, Inc. will post 4.13 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 28th. Shareholders of record on Tuesday, July 6th will be paid a dividend of $0.194 per share. This represents a $0.78 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Friday, July 2nd. Agilent Technologies’s dividend payout ratio is presently 23.78%.
A number of equities research analysts have weighed in on A shares. Citigroup boosted their price objective on Agilent Technologies from $150.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, May 26th. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $144.00 price objective for the company in a research note on Friday, May 28th. Wells Fargo & Company boosted their price objective on Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, May 26th. Canaccord Genuity upgraded Agilent Technologies from a “hold” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $100.00 in a research note on Thursday, May 13th. Finally, SVB Leerink upped their price target on Agilent Technologies from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 26th. Four research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the stock. Agilent Technologies presently has a consensus rating of “Buy” and an average price target of $113.84.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: What does a market perform rating mean?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.